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Abstract
Background: Anesthesia machines have been developed by the application of new technology for rapid and
easier control of anesthetic concentration. In this study, we used a test lung to investigate whether the time taken
to reach the target sevoflurane concentration varies with the rate of fresh gas flow (FGF) and type of anesthesia
machine (AM).
Methods: We measured the times taken to reach the target sevoflurane concentration (2 minimum alveolar
concentration = 4%) at variable rates of FGF (0.5, 1, or 3 L/min) and different types of AM (Primus®, Perseus®, and
Zeus® [Zeus®-F; Zeus® fresh gas mode, Zeus®-A; Zeus® auto-mode]). Concomitant ventilation was supplied using
100% O2. The AMs were connected to a test lung. A sevoflurane vaporizer setting of 6% was used in Primus
®,
Perseus®, and Zeus®-F; a target end-tidal setting of 4% was used in Zeus®-A (from a vaporizer setting of 0%). The
time taken to reach the target concentration was measured in every group.
Results: When the same AM was used (Primus®, Perseus®, or Zeus®-F), the times to target concentration shortened
as the FGF rate increased (P < 0.05). Conversely, when the same FGF rate was used, but with different AMs, the time
to target concentration was shortest in Perseus®, followed by Primus®, and finally by Zeus®-F (P < 0.05). With regards
to both modes of Zeus®, at FGF rates of 0.5 and 1 L/min, the time to target concentration was shorter in Zeus®-A
than in Zeus®-F; however, the time was longer in Zeus®-A than in Zeus®-F at FGF rate of 3 L/min (P < 0.05).
Conclusion: Shorter times taken to reach the target concentration were associated with high FGF rates, smaller
internal volume of the AM, proximity of the fresh gas inlets to patients, absence of a decoupling system, and use of
blower-driven ventilators in AM.
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Background
Technological advancements in anesthesia machines
(AM) have enabled rapid and easier control of anesthetic
concentration and reduced the risks or errors associated
with machine operation. However, previous studies have
demonstrated that a significant proportion of critical in-
cidents during anesthesia occur due to “the unfamiliarity
of the anesthesiologist with medical devices” [1, 2]. Fur-
thermore, Beydon et al. [3] reported that, between 1998
and 2005, there was an increase in the number of errors
made while operating medical devices used in anesthesia
and intensive care. Therefore, it is essential that anesthe-
siologists update their knowledge about AM.
The times required to reach the target concentration
of inhalational anesthetics varies greatly. To rapidly
reach target concentrations of inhalational anesthetics,
anesthesiologists generally use either higher fresh gas
flow (FGF) or the overpressure technique. However, the
time taken to reach the target concentration is also in-
fluenced by patient-, inhalational agent-, and equipment-
factors. Some factors that slow anesthetic uptake will
hasten the rate-of-rise of anesthetic concentration within
the lung. Patient- and inhalational agent-factors that
decrease anesthetic uptake actually hasten anesthetic
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induction and recovery; namely low solubility of blood/
gas coefficient in inhalational agents or low cardiac out-
put. In addition, the following equipment-factors affect
the time taken to reach the target concentration; FGF
rate, internal volume of the AM, composition of the
AM, target-controlled anesthesia (TCA) systems, etc.
[4–8]. Dräger™ has developed several types of AM, all of
which are used in clinical practice; however, from a tech-
nical point of view, these AMs differ significantly from
each other (Table 1).
The purpose of this study was to compare, using a test
lung, the times taken to reach the target sevoflurane
concentration of 4% (2 minimum alveolar concentration
[2 MAC]) at variable rates of FGF (0.5, 1, or 3 L/min)
and different types of AM (the last generation of
Dräger™ AMs: Primus®, Perseus®, and Zeus® [fresh gas




This prospective study was performed in vitro using a test
lung. Experiments were categorized into 10 different
groups at various rates of FGF (0.5, 1, or 3 L/min) and dif-
ferent types of AM (Primus®, Perseus®, or Zeus® [Zeus® -F;
Zeus® fresh gas mode, Zeus®-A; Zeus® auto-mode]; Dräger
Medical GmbH, Lübeck, Germany; Table 1). Before we
began our study, we ensured a routine check of the func-
tion and calibration of the anesthetic concentration of the
Primus®, Perseus®, Zeus® of the Dräger Company.
The AMs were connected to an anesthesia breathing
circuit (Hudson RCI®; Teleflex Inc., Morrisville, NC,
USA), with an internal volume of 1.2 L, a reservoir bag
(RB) of 3 L, and a test lung (Test lung 190®; Maquet
Critical Care AB, Solna, Sweden). The test lung had a
maximum capacity of 1 L, with an internal volume of
zero. Initially, free gas was supplied according to the
group’s FGF rate for 10 min to maintain a steady FGF
rate within the AM. The test lung was then ventilated in
the volume-controlled mode at a tidal volume of
600 mL, a respiratory rate of 12 breaths/min, and an in-
spiratory: expiratory ratio of 1:2.
To measure the sevoflurane concentration, an exter-
nal gas analyzer (Primus Infinity Vista XL®; Dräger
Medical GmbH, Germany) was used to obtain gas
samples at a rate of 200 mL/min at the Y-piece of
breathing circuit; the gas samples were not returned
to the system. Before the study, we ensured a routine
check of the function and calibration of the anesthetic
concentration of the the external gas analyzer of the
Dräger Company. The analyzer had an accuracy of
0.15%, a resolution of 0.1%, and a display range of 0–
11% for sevoflurane.
Classification of the comparison groups
We compared the time to target sevoflurane concentra-
tion in two sets of experiments, which were based on the
vaporizer operation mode in the AM (i.e., out-of-circle or
in-circle vaporizer). In the first set of experiments, we
compared the AMs with out-of-circle vaporizers (Primus®,
Perseus®, and Zeus®-F); in the second set, we compared the
different vaporizer operation modes within the multifunc-
tional AM (Zeus®-F with an out-of-circle vaporizer and
Zeus®-A with an in-circle vaporizer).
Measurement of the time taken to reach target
concentration
In Primus®, Perseus®, and Zeus®-F, the target sevoflurane
concentration was defined as 4% (approximately 2
MAC); the vaporizer was set to 6% from a previous set-
ting of 0%. In Zeus® -A, the target concentration was de-
fined as 4%; a target setting of 4% was established from
a previous vaporizer setting of 0%. The time to target
sevoflurane concentration was measured in seconds.
Each experimental trial was repeated 5 times at variable
rates of FGF (0.5, 1, or 3 L/min) and different types of
Table 1 The differences in the compositions and configurations of the anesthesia machines; Primus®, Perseus®, and Zeus® [12, 13, 15]
Primus® Perseus® Zeus®
Mode of anesthesia Fresh gas mode Fresh gas mode Fresh gas mode (Zeus®-F)
Auto-mode (Zeus®-A)
Type of ventilator Piston Blower-driven Blower-driven
Internal volume of anesthesia machine 4.7 L 2.1 L 2.0 L
Position of the fresh gas inlet (the rank for proximity to patient) Between ventilator
and absorber (2nd)
In front of ventilator
and absorber (1st)
Next to ventilator and absorber (3rd)
Presence of a decoupling system Yes No No
Type of vaporizer Bypass Bypass DIVA
Operation mode of vaporizer Out-of-circle Out-of-circle Out-of-circle (Zeus®-F)
In-circle (Zeus®-A)
Existence of TCA with a feedback control system No No Yes
DIVA direct injection of volatile anesthetics, TCA target-controlled anesthesia
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AMs. We also calculated the Fi/Ft ratio (Fi; the sevoflur-
ane concentration measured at the Y-piece of breathing
circuit, Ft; the target sevoflurane concentration) in all
groups.
In the present study, the inspiratory and end-tidal con-
centrations measured by the gas analyzer were equal, be-
cause there was no anesthetic uptake, as there is in
humans. We measured and recorded the mean sevoflur-
ane concentration waveform on the gas analyzer. After
each experimental trial, we renewed the CO2 absorber in
accordance with the type of AM (CLIC Absorber 800+®;
Dräger Medical GmbH, Germany). To completely wash
out the sevoflurane, we ventilated the AM using 100%
O2 at an FGF rate of 10 L/min for 30 min; the FGF rate
was then lowered to 1 L/min for 5 min. If there was a
rebound increase in sevoflurane concentration, the AM
was ventilated again at an FGF rate of 10 L/min for
10 min [9].
Statistical analysis
Statistical analysis was performed using SPSS 20 (IBM
Corporation, Armonk, NY, USA). The data are presented
as median (95% confidence interval). The times to target
concentration were compared among Primus®, Perseus®,
and Zeus®-F using the non-parametric Kruskal–Wallis
test; post-hoc multiple comparisons were conducted
using the Tukey test. The times to target concentration
were compared between Zeus®-F and Zeus®-A using the
non-parametric Wilcoxon signed-rank test. P-values
< 0.05 were considered statistically significant.
Results
We performed two kinds of comparisons depending on
the vaporizer operation mode used in the AM: (1) a
comparison among Primus®, Perseus®, and Zeus®-F; (2) a
comparison between Zeus®-F and Zeus®-A.
At different FGF rates, but in the same type of AM
(Perseus®, Primus®, and Zeus®-F), the time to target con-
centration shortened as the FGF rate increased (P < 0.05;
Table 2A, Fig. 1).
However, at the same FGF rate in different types of
AM (Perseus®, Primus®, and Zeus®-F), the time to target
concentration was shortest in Perseus®, followed by Pri-
mus®, and finally by Zeus®-F (P < 0.05; Table 2A).
Comparisons between the two modes of the Zeus®
showed that the time to target concentration was
shorter in Zeus®-A than in Zeus®-F at FGF rates of 0.5
and 1 L/min. However, at an FGF rate of 3 L/min, the
time was longer in Zeus®-A than in Zeus®-F (P < 0.05;
Table 2B, Fig. 1).
The Fi/Ft ratio curves from all groups are shown in
Fig. 1.
Discussion
The present study showed that the time to target sevo-
flurane concentration is shorter at higher FGF rates, and
that it varies in different types of AM used (Perseus®, Pri-
mus®, and Zeus®-F). In the comparison between Zeus®-A
and Zeus®-F, the time to target concentration varied at
variable rate of FGF.
Because of our study design, patient-factor and inhala-
tional agent- factor were excluded from the time to tar-
get concentration; that is, we used a test lung and a
single inhalational anesthetic (sevoflurane). In this way,
this experiment focused on equipment-factor. Kern et al.
[7] reported that, in toddlers and newborns, the time to
target concentration shortens at high FGF rates, at small
internal volumes of the AM, and at high minute ventila-
tions. In the present study, the Primus® [7, 12], Perseus®
[13], and Zeus® (Zeus®-F and Zeus®-A) [5, 6, 14, 15] dif-
fered in the following ways: (1) type of ventilator, (2) in-
ternal volume, (3) proximity of the fresh gas inlet to the
patient, (4) presence of the decoupling system, (5) type
of vaporizer, and (6) involvement of TCA (Table 1).
In the present study, given the same FGF rate, the
times to target sevoflurane concentration shortened in
the order of Perseus®, Primus®, Zeus®-F. Theoretically, the
time constant (τ = circuit’s internal volume/FGF rate)
Table 2 The times taken to reach the target sevoflurane
concentrations using a test lung (A) at variable rates of fresh gas
flow (FGF) and different types of anesthesia machine (Primus®,
Perseus®, and Zeus®-fresh gas mode), (B) at variable rates of FGF
and different modes in Zeus® (Zeus®-F; Zeus® fresh gas mode,
Zeus®-A; Zeus® auto-mode) using a lung model. The data are
presented as median (95% confidence interval) in seconds. At
different FGF rates, but in the same type of AM (Perseus®, Primus®,
and Zeus®-F), the time to target concentration shortened as the
FGF rate increased (P < 0.05; for simplicity, no statistical remarks
are included in the table). Identical data are shown for Zeus®-F
mode in Tables A and B. **P < 0.05 for comparisons with Zeus®-F.
TCA; target-controlled anesthesia
A.
FGF rate Primus® Perseus® Zeus®-F
(fresh gas mode)
0.5 L/min 1165 (1150–1185)† 920* (883–960) 1590*† (1528–1639)
1 L/min 534 (505–538)† 445* (428–474) 705*† (690–729)
3 L/min 155 (149–164)† 134* (121–137) 255*† (247–260)
B.
FGF rate Zeus ®-F (fresh gas mode) FGF rate Zeus®-A
(auto-mode)
0.5 L/min 1590 (1528–1639) Auto-control of
FGF by TCA
380 ** (374–389)
1 L/min 705 (690–729)
3 L/min 255 (247–260)
*P < 0.05 for comparisons with Primus®. † P < 0.05 for comparisons
with Perseus®
**P < 0.05 for comparisons with Zeus®-F
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characterizes the response time in which a circular breath-
ing system reaches its target concentration [10, 11]. We
calculated the circuit volume of each AM (the internal
volume of AM+ the volume of breathing circuit 1.2 L)
and the time constant (the circuit volume/FGF rate) at
variable rate of FGF and for different types of AM
(Table 3). As the FGF rate increased, the difference among
the AMs in terms of the time to target sevoflurane con-
centration tended to decrease. Importantly, the Perseus®
and Zeus® had similar circuit volumes (3.3 L and 3.2 L, re-
spectively) and time constants (6.6 and 6.4 min, respect-
ively, at an FGF 0.5 L/min) (Table 3). In contrast, the
Primus® had a circuit volume of 5.9 L and a time constant
of 11.8 min at an FGF 0.5 L/min (Table 3). Despite this,
there were significant differences in the time to target
sevoflurane concentration between Perseus® and Zeus®-F
(Table 2). We posit that these differences were due to the
equipment-factors other than known factors such as the
circuit volume and FGF rate [7].
The shortest time to target sevoflurane concentration,
obtained using the Perseus®, was likely due to the small
internal volume of the AM, the proximity of the fresh
gas inlet to the patient, the absence of a decoupling sys-
tem, and the rapid ventilation by a blower-driven venti-
lator (Table 1). The internal volumes of the AMs,
including the CO2 absorbers, but without the breathing
circuits, are 4.7 L for Primus®, 2.1 L for Perseus®, and
Fig. 1 The Fi/Ft ratio curves at variable rate of fresh gas flow (FGF) and different types of anesthesia machine (Primus®, Perseus®, and Zeus® [Zeus®-
F; Zeus® fresh gas mode, Zeus®-A; Zeus® auto-mode]). The Fi is the sevoflurane concentration measured at the Y-piece of breathing circuit, while
the Ft is the target sevoflurane concentration.)
Table 3 The circuit volume of anesthesia machine (AM) and
time constant at variable rates of fresh gas flow (FGF) and
different types of AM
Primus® Perseus® Zeus®-F (fresh gas mode)
The circuit volume of AM
(the internal volume of
AM + the volume of
breathing circuit 1.2 L)
5.9 L 3.3 L 3.2 L
Time constant (the circuit volume/FGF rate)
FGF rate 0.5 L/min 11.8 min 6.6 min 6.4 min
1 L/min 5.9 min 3.3 min 3.2 min
3 L/min 1.9 min 1.1 min 1.0 min
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2.0 L for Zeus® (Zeus®-F and Zeus®-A; Table 1) [12–14].
In the Perseus®, the fresh gas inlet is closest to the pa-
tient, followed by Primus®, and finally by Zeus® (Zeus®-F
and Zeus®-A; Table 1) [12–14]. Fukuda et al. [16] re-
ported that the proximity of the fresh gas inlet to the
patient improves the inspired/delivered ratios of sevo-
flurane during low-flow anesthesia. Moreover, only
Primus® has a decoupling system to prevent barotrauma,
which is caused by unexpected increases in tidal volume
[12]. In the decoupling system, fresh gas is diverted into
the RB during inspiration, and then from the RB into
the circular system during expiration [7, 12]. This causes
a delay in the time to target sevoflurane concentration
[7, 12]. Primus® also has a classical piston ventilator,
while Perseus® and Zeus® have the blower-driven ventila-
tors with rapid mixing [13, 14].
In the Primus® and Zeus®-F, the times to target sevo-
flurane concentration were longer than needed with
Perseus®, because (1) the fresh gas inlets were not close
to the patient in either Primus® or Zeus®, (2) Primus® has
a large internal volume, (3) Primus® has a decoupling
system, and (4) Zeus® has two modes of vaporization
with the direct injection of volatile anesthetics (DIVA;
Table 1) [5, 6, 12–14, 17]. The Primus® and Perseus® use
a semi-closed circuit system and a bypass vaporizer
(out-of-circle vaporization), whereas Zeus® is the multi-
functional system that can operate a semi-closed circuit
system (out-of-circle vaporization) or closed-circuit sys-
tem (in-circle vaporization) using the DIVA vaporizer. In
Zeus®-F mode (out-of-circle vaporization), the injected
sevoflurane is mixed with FGF in a mixing chamber next
to the ventilator; conversely, in Zeus®-A (in-circle
vaporization), the injected sevoflurane is vaporized im-
mediately into the internal circuit, independent of the
FGF [5, 6, 14]. Zeus®-A allows TCA, with rapid control
of sevoflurane concentration by blower-driven ventila-
tion and DIVA, whereas Zeus®-F introduces a delay to
the mixing process in the chamber next to the DIVA
vaporizer [5, 6, 15].
Before the investigation, we suspected that Zeus®-A
would require a shorter time to target sevoflurane con-
centration than Zeus®-F; however, at an FGF 3 L/min,
the opposite was true. One previous study showed that
Zeus®-A routinely nears the target setting of sevoflurane
early [5]. Thus, to avoid exceeding the target sevoflurane
concentration, the AM lowers the speed of the blower-
driven ventilator to gradually reach the target concentra-
tion [5]. In the present study, Zeus®-A reached a sevo-
flurane concentration of approximately 3.6% very
rapidly; there was then a considerable delay before the
target sevoflurane concentration of 4% was reached
(Fig. 1). With respect to the time to target sevoflur-
ane concentration in Zeus®-F and Zeus®-A, the
blower-driven ventilator with DIVA had a greater
effect on the time at FGF 0.5 and 1 L/min, but the
FGF rate itself had a greater effect on the time at an
FGF 3 L/min,
The Perseus®, the latest AM from Dräger, has a
blower-driven ventilator and a small internal volume;
the fresh gas inlet is close to the patient and it has a
classic out-of-circle vaporizer. However, it does not have
a decoupling system or a DIVA vaporizer [17]. In clinical
practice, rapid rises in target inhalational concentration
can be achieved using volatile induction and mainten-
ance anesthesia (VIMA). In such cases, it is better to use
a high FGF rate and a high vaporizer setting, as well as
an AM with a small internal volume, a blower-driven
ventilator, a fresh gas inlet that is close to the patient,
and no decoupling system [18].
One limitation of this study was that it did not involve
anesthetic uptake by humans. Furthermore, because we
measured the sevoflurane concentration at the Y-piece,
the recirculated circuit gas may not have mixed ad-
equately. Nevertheless, the results from our study using
a test lung will be valuable and helpful in understanding
the differences among the various AMs, as well as in
developing a new AM in the future.
Conclusions
In conclusion, the time taken to reach the target concen-
tration was affected by the FGF rate, as well as by the
composition and configuration of the AM. Apart from
the main factors, such as the rate of FGF rate and the in-
ternal volume of the AM, the time to target sevoflurane
concentration was also affected by other equipment-
factors in the AM: differences in the proximity of the
fresh gas inlet to the patient, the presence or absence of
a decoupling system, and the use of a blower-driven ven-
tilator with a DIVA vaporizer.
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